Obesity
GLP-1 for Teenagers: What the New Guideline Actually Says
The German AWMF guideline on adolescent obesity was updated early in 2026. For the first time, GLP-1 analogues are listed as a regular option - and that changes the conversation in many families.
The 2026 update of the AWMF guideline "Therapy and Prevention of Obesity in Childhood and Adolescence" is not a routine refresh. It was pulled forward because the evidence base for medication options in adolescents had shifted enough that the previous version no longer fit. For the first time, GLP-1 analogues - synthetic versions of the body's own satiety hormone - are listed as a regular treatment option, alongside lifestyle intervention, behavioural therapy and rehabilitation.
What changed in the guideline
The previous version recommended a multi-professional lifestyle intervention over six to twelve months as the primary route. Medication was the exception. The 2026 version adds GLP-1 analogues like liraglutide for adolescents as an additional option above a defined severity threshold and minimum age. They do not replace lifestyle intervention; they run alongside it.
Important framing: the change does not mean every child with excess weight will now receive medication. The guideline defines clear criteria - BMI percentile, comorbidities, history of prior therapy - assessed only by a clinician in the individual case.
How GLP-1 analogues work
GLP-1 stands for glucagon-like peptide-1, a hormone the gut releases after eating. It signals satiety to the brain, slows gastric emptying and regulates insulin release. In many people with obesity this satiety signal is weaker or arrives late. GLP-1 analogues are synthetic versions of this hormone that stay active in the body longer.
The effect: the brain receives the "full" signal earlier and more clearly. Hunger weakens, satiety lasts longer. That is biochemistry, not willpower. This is the point that often relieves parents first: it isn't a lack of discipline, it's a body signal that arrives too quietly.
The chat blocks below are translated 1:1 from the German live answers in the app.
User question
My son (15) has been offered liraglutide (GLP-1) by his paediatrician. I don't understand whether this is really necessary now or whether we shouldn't try more first.
Rehavio (parent)
This uncertainty is completely understandable - a medication for a 15-year-old feels like a big step.
What liraglutide does in the body: it is a GLP-1 receptor agonist, meaning it mimics a body-own messenger that is normally released after eating. This messenger signals satiety to the brain and slows gastric emptying. In many adolescents with obesity this exact signal does not work reliably - not because they "aren't paying attention" but because hormonal regulation is biologically set differently.
This is not a sign that other measures have "failed". Movement, dietary changes and psychological support - the kind your son is receiving in Satteldüne - work through different pathways. A medication that supports satiety regulation can run in parallel because it acts on a different mechanism: directly on the hunger and satiety system in the brain.
Whether this is the right time, whether the rehab stay should be completed first, which findings speak for or against starting therapy - those are questions only the treatment team that knows your son and his course can answer.
What I would suggest: ask the doctors here in Satteldüne directly. They can put your paediatrician's proposal in context and discuss with you what makes sense.
This answer comes from Rehavio. You can ask your own questions about your situation.
What the guideline does not say
This is the part that often gets lost in the news. The guideline does not say GLP-1 is a shortcut. It does not say medication replaces rehab or behavioural work. It does not say there are no side effects - nausea, gastrointestinal symptoms and questions about long-term safety in adolescents are explicitly named. It does not say this is a lifelong medication or one that "fixes" the condition once stopped.
Trial data on liraglutide in adolescents (e.g. SCALE Teens) show meaningful BMI reduction versus placebo, but also: a portion of weight returns after stopping. That is not treatment failure. It reflects the biology of the set-point theory - the body actively defends its stored weight. GLP-1 shifts the set-point, it does not erase it.
Common misunderstandings you will hear now
"It's the same as Ozempic for adults." Same drug class, but indication and dosing in adolescents follow their own trials and approvals. The guideline addresses paediatric use explicitly.
"If the injection helps, that's the easy way." The medication only works while it is given, and only in combination with behavioural and dietary work. Without that, weight returns more often.
"My child is just a bit chubby, they will grow out of it." Epidemiological data - DAK Children and Youth Report 2025, RKI-KiGGS - show that the post-pandemic weight gain in adolescents does not grow itself out. That is precisely why the guideline was updated.
Talking to your child about it
A medication option often raises a question adolescents do not voice directly: is something wrong with my body? That question shapes how your child experiences the therapy and whether it holds long-term. How you have the conversation matters at least as much as the medical decision itself.
User question
I'm afraid my son will get the feeling that his body is broken and needs to be fixed. How do I talk to him about the treatment decision?
Rehavio (parent)
That fear is justified - and the fact that you're asking yourself this before he arrives makes a real difference.
The most important thing first: the picture your son develops of his body depends strongly on how things are said, not only on what is said.
His body is not broken. It regulates hunger, satiety and energy storage in a particular way - one shaped by genetics, hormones and early imprinting. That is not a defect, it is biology. When you talk with him, a concrete shift in language helps: not "your body works wrong", but "your body has learned a particular way of dealing with energy - let's look at it together."
Especially with an adolescent, a conversation about a treatment decision - particularly one that is concrete and perhaps new to him - is a question of control. Not "this was decided for you" but "you know what's going on in you, we can talk about what you want to understand."
What most prevents the "needs to be fixed" picture: when he notices that you don't want to change his body, but to give him more options to feel comfortable in it. That is not a linguistic trick - it is a real difference in stance.
Concrete phrasings for the conversation can be developed together with the rehab team in Satteldüne, because they know his context.
Questions to clarify in advance
This is not advice but a structure for the conversation with your treating practice: which BMI percentile and which comorbidities are present? Which non-pharmacological steps have been tried, and over what period? Who handles ongoing care - paediatrics, paediatric endocrinology, the rehab clinic? Which side effects are likely in the first weeks? What happens if the medication is stopped after some time? Who covers the cost - indication, off-label or approved use?
A bright spot
The new guideline quietly shifts the social view of adolescent obesity from blame towards biology. Once that lands, a medication option can be placed more calmly - as one tool among several, not as a verdict on a child or on parenting. That GLP-1 analogues are even being discussed means above all this: there are more options than two years ago, and more language for what is happening in the body.
Rehavio explains the body mechanisms behind obesity - set-point, hormones, satiety signals - in a language that adolescents and parents share. Rehavio does not provide diagnoses, does not give dosing recommendations and does not replace medical or therapeutic care. What remains: context, reframing, language for what is happening in the body.
